ET‐1‐associated vasomotion and vasospasm in lymphatic vessels of the guinea‐pig mesentery
Open Access
- 1 December 2003
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 140 (8), 1399-1413
- https://doi.org/10.1038/sj.bjp.0705573
Abstract
In vitro experiments were performed to investigate the actions of endothelin‐1 (ET‐1) on vasomotion and vasospasm in guinea‐pig mesenteric lymphatics. ET‐1 modulated lymphatic vasomotion independent of the endothelium, with lower concentrations (10 nM) increasing lymphatic vasomotion and higher concentrations (100 nM) causing vasospasm. ET‐1‐induced increases in vasomotion were accompanied by an increase in tonic [Ca2+]i. These actions were inhibited by the ETA receptor antagonist BQ‐123 (1 μM), the phospholipase C (PLC) inhibitor U73122 (5 μM), removal of extracellular Ca2+, chelation of intracellular Ca2+ with BAPTA/AM (10 μM), the store Ca2+‐ATPase inhibitor thapsigargin (1 μM), caffeine (10 mM) and the inositol 1,4,5‐trisphosphate (IP3) receptor blocker heparin and 2‐APB (30 μM). In contrast, the ETB receptor antagonist BQ‐788 (1 μM), ryanodine (1 & 20 μM), pertussis toxin (PTx) or Cs+ had no significant actions on vasomotion or the magnitude of increase in tonic [Ca2+]i. ET‐1‐induced vasospasm was accompanied by a transient increase in smooth muscle [Ca2+]i followed by a sustained plateau, an action that was abolished by removal of extracellular Ca2+, but only marginally inhibited by nifedipine (1 μM). Caffeine (10 mM), SKF 96165 (30 μM) or U73122 (5 μM) together with nifedipine (1 μM) abolished ET‐1‐induced vasospasm and increase in [Ca2+]i. These results indicate that ET‐1 increases lymphatic vasomotion by acting on smooth muscle ETA receptors and activation of G‐protein‐PLC‐IP3 cascade, which is known to cause pacemaker Ca2+ release and resultant pacemaker potentials. High concentrations of ET‐1 cause a failure in Ca2+ homeostasis causing vasospasm, triggered by excessive Ca2+ influx primarily through store‐operated channels (SOCs) with L‐Ca2+ voltage‐operated channels (VOCs) also contributing, but to a much lesser extent. British Journal of Pharmacology (2003) 140, 1399–1413. doi:10.1038/sj.bjp.0705573This publication has 78 references indexed in Scilit:
- Preconditioning of Coronary Artery Against Vasoconstriction by Endothelin-1 and Prostaglandin F2α During Repeated Downregulation of ∊-Protein Kinase CJournal of Cardiovascular Pharmacology, 2000
- The Effects of 2-Aminoethoxydiphenyl Borate, a Novel Inositol 1,4,5-Trisphosphate Receptor Modulator on Myometrial ContractionsBiochemical and Biophysical Research Communications, 1999
- Nicardipine modification of endothelin-1 effects on visual evoked potentialJapanese Journal of Ophthalmology, 1997
- Role of Extracellular Ca 2+ in Subarachnoid Hemorrhage−Induced Spasm of the Rabbit Basilar ArteryStroke, 1996
- Nonpeptide endothelin antagonist. Cerebrovascular characterization and effects on delayed cerebral vasospasm.Stroke, 1994
- Endothelin: An Endothelium-Derived Vasoactive PeptideJournal of Reconstructive Microsurgery, 1994
- Endothelin: A potent vasoconstrictor associated with coronary vasospasmLife Sciences, 1989
- Endothelin action on vascular smooth muscle involves inositol trisphosphate and calcium mobilizationBiochemical and Biophysical Research Communications, 1989
- Molecular mechanism of action of the vasoconstrictor peptide endothelinBiochemical and Biophysical Research Communications, 1988
- Heparin inhibits the inositol 1,4,5-trisphosphate-dependent, but not the independent, calcium release induced by guanine nucleotide in vascular smooth muscleBiochemical and Biophysical Research Communications, 1988